AMD3100 (Plerixafor), Inhibitor

AMD3100 (Plerixafor)

Cat. Num. AAA385227

• Purity: >98%
• Synonyms: AMD3100 (Plerixafor); inhibitor

• Purity/Purification: >98%
• Form/Format: Powder
• Concentration: 0.1 mM: 19.89 mL (1 mg); 99.45 mL (5 mg); 198.89mL (10 mg); 0.5 mM: 3.98 mL (1 mg); 19.89 mL (5 mg); 39.78 mL (10 mg); 1 mM: 1.99 mL (1 mg); 9.94 mL (5 mg); 19.89 mL (10 mg); 5 mM: 0.4 mL (1 mg); 1.99 mL (5 mg); 3.98 mL (10 mg) (varies by lot)

• CAS Number: 110078-46-1
• Formula: C28H54N8
• SMILES: C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3
• Actions: Antagonist
• In Vivo Solvent: 30% propylene glycol, 5% Tween 80, 65% D5W
• Solubility (DMSO): <1 mg/mL (<1 mM)
• Solubility (Ethanol): 100 mg/mL (198.89 mM)
• Solubility (in vivo): 30 mg/mL
• Solubility (Water): 3 mg/mL heating (5.96 mM)
• Availability: We cannot ship this item to Switzerland, Italy, Germany, France and Austria.
• Preparation and Storage: at -20 degree C 3 years Powder

Chemical Structure

Related Product Information for AMD3100 (Plerixafor), inhibitor

Plerixafor is an immunostimulant used to multiply hematopoietic stem cells and it is a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation.

References

Ichimizu S, .et al. Cell-penetrating mechanism of intracellular targeting albumin: Contribution of macropinocytosis induction and endosomal escape, J Control Release, 2019, May 10;304:156-163 PMID: 31082432
Nan Li, .et al. LPS-induced CXCR7 expression promotes gastric Cancer proliferation and migration via the TLR4/MD-2 pathway, Diagn Pathol, 2019, Jan 12;14(1):3 PMID: 30636642
Thida W, .et al. The role of conventional antibodies targeting the CD4 binding site and CD4-induced epitopes in the control of HIV-1 CRF01_AE viruses, Biochem Biophys Res Commun, 2018, Nov 20. pii: S0006-291X(18)32477-X PMID: 30470571
Henry R. Hampton, .et al. Microbe-dependent lymphatic migration of neutrophils modulates lymphocyte proliferation in lymph nodes, Nat Commun, 2015, 6: 7139 PMID: 25972253